Treatment of OVA-sensitized and challenged mice with HRS ameliorated the pathological changes in airways (Fig. 7A), reduced the number of BALF inflammatory cell count (Fig. 7B), alleviated airway hyperresponsiveness (Fig. 7C), and reduced BALF levels of cytokines and IgE (Fig. 7D–G). This evidence concerns the gene IGHE and airway hyperresponsiveness.